Skip to main content
. 2022 Jun 9;2022:2756682. doi: 10.1155/2022/2756682

Figure 3.

Figure 3

Summary of meta-analyses comparing RIV and API versus SoC in VTE for the recurrent DVT. API: apixaban; CI: confidence interval; DVT: deep vein thrombosis; HR: hazard ratio; Np: number of patients; Ns: number of studies; RIV: rivaroxaban; SoC: standard of care; VKA±Hep: vitamin K antagonist±heparins; VTE: venous thromboembolism; N/A: not applicable. Green marks represent results indicating statistically lower event rate in the NOAC groups.